Morning Sickness Clinical Trial
Official title:
Effectiveness of a Natural Non-medicinal Freezie Remedy to Alleviate Morning Sickness
NCT number | NCT01668940 |
Other study ID # | 1000031589 |
Secondary ID | |
Status | Terminated |
Phase | N/A |
First received | |
Last updated | |
Start date | August 2012 |
Est. completion date | July 2015 |
Verified date | January 2020 |
Source | The Hospital for Sick Children |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary objective of this study is to assess the effectiveness of Lillipops in the improvement of morning sickness symptoms. Secondary objectives are to assess if there are any changes to concurrent symptoms that may intensify NVP, such as metallic taste or gastrointestinal issues (e.g. heartburn, acid reflux, indigestion and gas), as well as preference for freezie flavours.
Status | Terminated |
Enrollment | 54 |
Est. completion date | July 2015 |
Est. primary completion date | July 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: - Pregnancy between 4 and 12 weeks gestation. - Pregnant women with NVP, regardless of treatment (if any) for their NVP. - Provide the signed informed consent form prior to initial interview. - Able to come in person to Sick Kids or meet at an agreed location. Exclusion Criteria: - Gestational age beyond 12 weeks of pregnancy. - Pregnant women less than 18 years of age. - Women who are not proficient in the English language. - Unable to consume any of the ingredients listed in Lillipops or Mr. Freeze freezies due to allergies, medication interactions or other reasons. - Women refusing to avoid sources of ginger products for the duration of the study. |
Country | Name | City | State |
---|---|---|---|
Canada | The Hospital for Sick Children | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
The Hospital for Sick Children |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Improvement of Nausea and Vomiting of Pregnancy (NVP) | To assess the effectiveness of Lillipops in the improvement of NVP symptoms. The primary endpoint of interest is the severity of NVP as compared between the 4 groups, defined according to the PUQE-24 (pregnancy-unique quantification of emesis and nausea) scoring system for nausea and vomiting of pregnancy that was developed and validated by Motherisk. | Baseline, +1, +3, +5, +7 days | |
Secondary | Concurrent Symptoms | To assess if there are any changes to concurrent symptoms that may intensify NVP, such as metallic taste or gastrointestinal issues (e.g. heartburn, acid reflux, indigestion and gas). The secondary endpoint of interest is the effect of the 4 groups on the status of concurrent symptoms that may intensify NVP, such as metallic taste or gastroesophageal reflux disease, as well as preference for freezie flavours, according to the PUQE-24 (pregnancy-unique quantification of emesis and nausea) scoring system for nausea and vomiting of pregnancy that was developed and validated by Motherisk. | Baseline, +1, +3, +5, +7 days | |
Secondary | Freezie Flavour Preference | To assess preference for freezie flavours. | Baseline, +1, +3, +5, +7 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
Completed |
NCT02300155 -
Improving Multivitamin Supplementation to Pregnant Women
|
Phase 4 | |
Recruiting |
NCT05289557 -
The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
|
Phase 3 | |
Completed |
NCT02541682 -
Assessment of the Relationship Between Affective Temperament and the Severity of Nausea and Vomiting in Early Pregnancy
|
N/A | |
Terminated |
NCT02045901 -
A Multicenter Trial of the Efficacy and Safety of Diclegis® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
|
Phase 4 | |
Completed |
NCT03513536 -
The Effect of Scent on Pregnancy Induced Nausea, Vomiting, and Quality of Life
|
N/A |